Inventor

MURPHY BRIAN R

US83 patents

⚠️ This page may combine multiple inventors who share the name “MURPHY BRIAN R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

MURPHY BRIAN R

US HEALTH

Attenuated respiratory syncytial virus vaccine compositions

Attenuated chimeric respiratory syncytial virus

Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis

Attenuated dengue virus comprising mutations in the NS3 gene

Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens

Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2

Attenuated respiratory syncytial virus vaccine compositions

Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Attenuated parainfluenza virus (PIV) vaccines

Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)

Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes

Live attenuated virus vaccines for la crosse virus and other bunyaviridae

Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines

Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines

Recombinant human metapneumovirus and its use

Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

WHITEHEAD STEPHEN S

Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4

Development of dengue virus vaccine components

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4

Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae

SCRIPPS RESEARCH INST

Human neutralizing monoclonal antibodies to respiratory syncytial virus

Human neutralizing monoclonal antibodies to respiratory syncytial virus

Human neutralizing monoclonal antibodies to respiratory syncytial virus

THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICES

Development of dengue virus vaccine components

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

US HEALTH EDUCATION & WELFARE

Temperature-sensitive recombinant mutant viruses and a process for producing same

ST JUDE CHILDRENS RES HOSPITAL

Human use of avian-human reassortants as vaccines for influenza A virus

US GOVERNMENT

Development of dengue virus vaccine components

ZENG JIAN

Detection of boilerplate content

USA

Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

INTRACEL RESOURCES LLC

Neutralizing monoclonal antibodies to respiratory syncytial virus

PILKINGTON GLENN R

Neutralizing monoclonal antibodies to respiratory syncytial virus

CORNELL RES FOUNDATION INC

Temperature sensitive reassortant viruses and a vaccine against equine influenza

THE US SECRETARY DEPT OF HEALTH & HUMAN SERVICES

Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein

US OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH WASHINGTON D C

Attenuated dengue virus comprising mutations in the NS3 gene

US SEC THE DEPT OF HEALTH & HUMAN SERVICES

Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

PLETNEV ALEXANDER G

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

INTEL CORP

Safe code-motion of dangerous instructions during compiler optimization